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Dietary Nitrate Supplementation Protects Against
Doxorubicin-Induced Cardiomyopathy
by Improving Mitochondrial Function
Shu-Guang Zhu, MD, PHD,* Rakesh C. Kukreja, PHD,* Anindita Das, PHD,* Qun Chen, MD, PHD,*
Edward J. Lesnefsky, MD,*† Lei Xi, MD*
Richmond, Virginia
Objectives The aim of this study was to test the hypothesis that long-term dietary nitrate supplementation protects against
doxorubicin-induced cardiomyopathy by improving ventricular function and reducing mitochondrial respiratory
chain damage.
Background Doxorubicin is a powerful anthracycline antibiotic used to treat divergent human neoplasms. Its clinical use is
limited because of severe cardiotoxic side effects. Dietary nitrate and nitrite are essential nutrients for mainte-
nance of steady-state tissue levels of nitric oxide and may play a therapeutic role in diseases associated with
nitric oxide insufficiency or dysregulation. Dietary nitrate and nitrite supplementation alleviates myocardial injury
caused by ischemia-reperfusion and cardiac arrest–resuscitation.
Methods Adult male CF-1 mice were given a single dose of doxorubicin (15 mg/kg intraperitoneally), and left ventricular
contractile function was assessed 5 days later using both echocardiography and pressure-volume Millar catheter-
ization. A nitrate supplementation regimen (1 g/l sodium nitrate in drinking water) was started 7 days before
doxorubicin injection and continued thereafter. Cardiomyocyte necrosis and apoptosis, tissue lipid peroxidation,
and plasma nitrate and nitrite levels were assessed. In addition, mitochondrial complex I activity, oxidative phos-
phorylation capacity, and hydrogen peroxide generation were determined in parallel experiments.
Results Doxorubicin caused impairment of ventricular contractility and cell death, which were significantly reduced by
nitrate supplementation (p  0.05). These cardioprotective effects were associated with a significant decrease
in tissue lipid peroxidation. Nitrate supplementation significantly preserved mitochondrial complex I activity and
oxidative phosphorylation and attenuated hydrogen peroxide generation after doxorubicin treatment.
Conclusions Long-term oral intake of inorganic nitrate attenuates doxorubicin-induced ventricular dysfunction, cell death, oxi-
dative stress, and mitochondrial respiratory chain damage. Nitrate could be a promising therapeutic agent
against doxorubicin-induced cardiotoxicity. (J Am Coll Cardiol 2011;57:2181–9) © 2011 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.024Doxorubicin (DOX) (with trade names such as Adriamycin
and Rubex) is a broad-spectrum and potent anthracycline
antibiotic that has been used to treat a variety of human
neoplasms (1). Despite its anticancer efficacy, the clinical
use of DOX is often limited by dose-dependent cardiotox-
icity, which may lead to irreversible dilated cardiomyopathy
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accepted January 11, 2011.and heart failure (2). The cardiotoxicity of DOX involves
increased oxidative stress in cardiomyocytes, alteration of
mitochondrial energetics, and a direct effect on deoxyri-
bonucleic acid. However, the optimal therapeutic ap-
proaches for protection against DOX cardiotoxicity have
not been identified. This is because most of the tested
agents (such as antioxidants and beta-adrenergic receptor
See page 2190
blockers) have pronounced clinical disadvantages, includ-
ing a decline in high-density lipoprotein level, an inabil-
ity to prevent mortality, weight loss, and potentiation of
myelosuppression (3).
Nitric oxide (NO) is essential for the integrity of the
ardiovascular system, and decreased production and/or bio-
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Nitrate Intake Reduces Doxorubicin Cardiotoxicity May 24, 2011:2181–9availability of NO lead to the de-
velopment of cardiovascular dis-
orders (4) and heart failure (5).
NO protects against ischemia-
reperfusion (I/R) injury induced by
ischemic or pharmacological pre-
conditioning (6), which could in-
volve inducible nitric oxide syn-
thase (iNOS) and endothelial nitric
oxide synthase (eNOS) (7,8). The
role of NO in protection against
DOX-induced cardiotoxicity with
the phosphodiesterase-5 inhibitor
sildenafil was suggested by our
group (9). Moreover, a possible role
of NO in protection against DOX-
induced cardiotoxicity was indicated
by beta-adrenergic blockers (10) or
statins (11), because these drugs in-
crease iNOS and eNOS messenger
ribonucleic acid and protein levels in
myocardium (12) and cardiomyo-
cytes (13).
In addition to L-arginine-
NOS-dependent NO synthesis,
the NOS-independent mecha-
nisms of NO generation also
convert nitrate to nitrite to NO
n vivo via both enzymatic reduction (e.g., xanthine oxi-
oreductase [14]) and nonenzymatic acidic disproportion-
tion (15). There are numerous colonies of bacteria in the
ammalian oral cavity and intestine that can reduce nitrate
o nitrite in vivo (16). The nitrate-nitrite-NO pathway is a
omplementary system to the NOS-dependent pathway for
nsuring sufficient NO production, especially under patho-
hysiological situations, including hypoxia and acidosis,
hen the oxygen-dependent NOS activity is compromised
17,18). Because a substantial portion of nitrate and nitrite
n the blood and tissue is derived from dietary sources, the
ietary supplementation of nitrate or nitrite protects against
yocardial I/R injury (19,20) and cardiac arrest–
esuscitation, reduces hypertension (21), and improves en-
othelial and platelet function as well as exercise perfor-
ance (22).
In this context, the present study was designed to test the
ypothesis that long-term nitrate supplementation may
rotect against ventricular dysfunction and cardiomyocyte
oss from DOX-induced cardiomyopathy. We also investi-
ated whether mitochondria are protected by nitrate, be-
ause DOX accumulates mainly in mitochondria and cell
uclei (23). Because DOX enhances reactive oxygen species
ROS) generation in cardiac mitochondria (24,25), we
tudied the effect of nitrate and nitrite in reducing oxidative
tress in the mitochondria. Because of the potential role of
ransient blockade of the mitochondrial complex I in nitrite-
Abbreviations
and Acronyms
DOX  doxorubicin
eNOS  endothelial nitric
oxide synthase
ETC  electron transport
chain
H2O2  hydrogen peroxide
iNOS  inducible nitric
oxide synthase
I/R  ischemia-reperfusion
LV  left ventricular
NADH  nicotinamide
adenine dinucleotide
NaNO3  sodium nitrate
NO  nitric oxide
NOx  nitric oxide
oxidation products
NOS  nitric oxide
synthase
ROS  reactive oxygen
species
TUNEL  terminal
deoxynucleotidyl
transferase deoxyuridine
triphosphate nick end
labelingnduced anti-ischemic protection (26), we also investigatedhe effect of nitrate on DOX-induced damage of the
itochondrial electron transport chain (ETC).
ethods
nimals. Adult male CF-1 outbred mice were purchased
rom Harlan Sprague Dawley, Inc. (Frederick, Maryland).
he animal experimental protocol was approved by the
nstitutional Animal Care and Use Committee of the
irginia Commonwealth University.
xperimental protocol. As illustrated in Online Figure 1A,
ice were administered a single dose of DOX intraperi-
oneally (15 mg/kg dissolved in saline; DOX group, n 
) or volume-matched saline (0.2 ml; control group, n 
). Another group of mice (nitrate  DOX group, n  8)
eceived sodium nitrate (NaNO3) added to their drinking
ater at a concentration of 1 g/l (12 mmol/l) for 7 days
efore DOX injection on day 8. The nitrate treatment
egimen was continued throughout the post-DOX pe-
iod. A control group of mice were given nitrate alone
nitrate group, n  8). This oral dose of NaNO3 has been
hown to be cardioprotective against I/R injury (19). Five
ays later (on day 13), left ventricular (LV) function was
ssessed on echocardiography under light anesthesia and
ubsequently with a Millar catheter (Millar Instruments,
nc., Houston, Texas) inserted into the LV cavity under
urgical anesthesia.
To determine the efficacy of nonoral nitrate, a subset of
ice were subcutaneously implanted with a micro-osmotic
ump (ALZET model 1002, ALZET Osmotic Pumps,
nc., Cupertino, California), which continuously delivered
aNO3 solution (1 g/l concentration) or saline (as sham
controls) at a rate of 0.25 l/h for 13 days. The nitrate-
nfused and saline-infused mice received DOX injection (15
g/kg intraperitoneally) on day 8 (n  7 per group).
easurement of DOX cytotoxicity in vitro. As illustrated
n Figure 1B, mice with or without 7 days of nitrate
upplementation were sacrificed on day 8, and cardiomyo-
ytes were isolated and exposed to 1 mol/l DOX by adding
to cell culture medium. Myocyte necrosis and apoptosis
were quantified 18 h later using trypan blue exclusion and
terminal deoxynucleotidyl transferase deoxyuridine triphos-
phate nick end labeling (TUNEL) assays.
Echocardiographic assessment of ventricular contractile
function. Echocardiography was performed using the
Vevo770 imaging system (VisualSonics Inc., Toronto, On-
tario, Canada).
Measurement of LV hemodynamic parameters. After
echocardiographic assessment, a microtip pressure-volume
catheter transducer (Millar Instruments, Inc.) was inserted
into the right carotid artery and advanced into the LV
cavity. LV systolic and end-diastolic pressures, the maximal
slope of the systolic pressure increment (dP/dtmax) and
diastolic pressure decrement (dP/dtmax), heart rate, and
aortic blood pressure were recorded on a beat-by-beat basis.
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May 24, 2011:2181–9 Nitrate Intake Reduces Doxorubicin CardiotoxicityMeasurement of plasma nitrate and nitrite. Blood sam-
ples were collected from mice that underwent 4 different
treatment conditions (n  6 per group) and centrifuged to
collect the plasma. Nitrate and nitrite were measured with a
Sievers NO analyzer (model 280NOA, GE Analytical
Instruments, Boulder, Colorado).
Measurement of mitochondrial oxidative phosphorylation
and enzyme activities. Oxidative phosphorylation was stud-
ied in the isolated mitochondria using glutamate and malate
(complex I) and succinate (complex II) as substrates to localize
defects within the ETC. Enzyme activities of complex I
(nicotinamide adenine dinucleotide [NADH]:duroquinone
oxidoreductase) and NADH dehydrogenase (proximal
segment of complex I) were determined.
ssessment of lipid peroxidation. Lipid peroxidation in
the cardiac tissues was determined by measuring malondi-
aldehyde and 4-hydroxyalkenals using a colorimetric assay
kit (Bioxytech LPO-586, OXIS International, Beverly
Figure 1 Echocardiographic Assessment
of LV Contractile Function
Significant declines in left ventricular (LV) ejection fraction (A) and fractional short-
ening (B) in the doxorubicin (DOX)-treated group were observed compared with the
control mice. Mice receiving nitrate supplementation had partial restoration of
contractile indexes. Data are expressed as mean  SEM (n  8 per group).
*p  0.05 versus all other groups; #p  0.05 versus control or nitrate group.Hills, California).Measurement of hydrogen peroxide. The rate of hydro-
gen peroxide (H2O2) generation in mitochondria (n 5 per
roup) was determined using oxidation of the fluorogenic
ndicator Amplex Red (Invitrogen Corporation, Carlsbad,
alifornia) in the presence of horseradish peroxidase.
tatistical analysis. Data are presented as group mean 
EM. Statistical analysis was performed using 1-way anal-
sis of variance with subsequent Student-Newman-Keuls
ost hoc tests for pairwise comparisons among the 4
reatment groups. Unpaired t tests were used to compare
treatment groups in the study with subcutaneous infusion
f nitrate. p values 0.05 were considered statistically
ignificant.
Please see the Online Appendix for a complete descrip-
ion of the methods.
esults
itrate supplementation ameliorates DOX-induced LV
ontractile dysfunction. LV ejection fraction and frac-
ional shortening decreased significantly in the DOX group
ompared with the control group after 5 days of treatment
Fig. 1), which improved with nitrate supplementation
efore and after DOX injection (p  0.05, nitrate  DOX
s. DOX; n  8 per group) (Fig. 1). Similar results were
btained with invasive measurements on Millar catheteriza-
ion. DOX-induced LV systolic (Figs. 2A and 2C) and
iastolic (Figs. 2B and 2D) dysfunction was significantly
educed by nitrate supplementation. In addition, heart rate
Fig. 2E) and mean aortic blood pressure (Fig. 2F) were
ecreased by DOX administration and were partially atten-
ated by nitrate (p  0.05, nitrate  DOX vs. DOX; n 
per group). Nitrate alone had no effect on these functional
arameters (Figs. 2A to 2F).
itrate supplementation enhances plasma levels of nitrate
nd nitrite. Oral nitrate supplementation enhanced
lasma nitrate (Fig. 3A) and nitrite (Fig. 3B) compared
ith the control group (p  0.05). DOX treatment also
levated plasma nitrate levels (likely through the en-
anced NOS-dependent NO synthesis triggered by
OX). In contrast, nitrite levels did not increase in
OX-treated groups with or without nitrate supplemen-
ation (Figs. 3A and 3B), suggesting impeded nitrate-to-
itrite conversion. Overall NO oxidation products (NOx)
ere increased in the nitrate and nitrate  DOX groups
ompared with the control and DOX groups (p  0.05)
Fig. 3C).
itrate supplementation reduces DOX-induced cardiomy-
cyte death in vitro. The number of both trypan blue–
ositive (necrotic) and TUNEL-positive (apoptotic) cardi-
myocytes increased after 18 h of exposure to 1 mol/L
DOX in vitro (p 0.01, control vs. DOX; n 4 per group)
(Fig. 4). Basal cell viability was not altered with nitrate
supplementation. However, cardiomyocytes from nitrate-
2184 Zhu et al. JACC Vol. 57, No. 21, 2011
Nitrate Intake Reduces Doxorubicin Cardiotoxicity May 24, 2011:2181–9treated mice were more resistant to DOX-induced cytotox-
icity, as indicated by reductions in necrosis (Fig. 4A) and
apoptosis after 18 h of DOX exposure (Fig. 4B) compared
with the DOX group (p  0.01 for necrosis, p  0.05 for
apoptosis).
Nitrate supplementation preserves oxidative phosphorylation
in mitochondria. DOX interferes with mitochondrial respira-
Figure 2 Evaluation of Left Ventricular Hemodynamic Function
Significant declines in left ventricular systolic pressure (LVSP) (A), positive and ne
icant increase in left ventricular end-diastolic pressure (LVEDP) (B) were observed
Nitrate supplementation restored contractile function. Data are expressed as mea
control or nitrate group.tion at several levels of the ETC. It diverts electrons fromcomplex I of the respiratory chain to generate the semiquinone
free radical, initiating a futile redox cycle leading to a stimula-
tion of oxygen free radical generation (27,28). To demonstrate
the effect of nitrate supplementation on oxidative phosphory-
lation after DOX treatment, cardiac mitochondria were iso-
lated from treated groups (Online Fig. 1A). DOX treatment
markedly decreased oxidative phosphorylation when glutamate
Millar Microtip Catheter
dP/dtmax (C, D), heart rate (E), and mean aortic blood pressure (F) and a signif-
doxorubicin (DOX)-treated mice compared with the saline-treated controls.
EM (n  8 per group). *p  0.05 versus all other groups; #p  0.05 versusWith
gative
in the
n  Sand malate were used as complex I substrates. The rate of
2185JACC Vol. 57, No. 21, 2011 Zhu et al.
May 24, 2011:2181–9 Nitrate Intake Reduces Doxorubicin Cardiotoxicitysuccinate oxidation was not altered in the DOX-treated group
(n 6 per group) (Fig. 5A). Nitrate supplementation restored
Figure 3 Plasma Levels of Nitrate, Nitrite, and NOx
Assessment of plasma levels of nitrate (A), nitrite (B), and the sum of nitrate
and nitrite (i.e., nitric oxide oxidation products [NOx]) (C). Data are expressed
as mean  SEM (n  6 per group). *p  0.05 versus all other groups;
#p  0.05 versus doxorubicin (DOX) group.oxidative phosphorylation with glutamate and malate as sub-strates, showing protection of complex I against DOX-induced
damage (Fig. 5A).
Nitrate supplementation prevents DOX-induced damage
of mitochondrial NADH dehydrogenase. To further local-
ize the site of the defect in complex I, enzyme activities of
complex I (NADH/duroquinone oxidoreductase) and
NADH dehydrogenase (the proximal part of complex I)
were measured in the homogenates. DOX treatment de-
creased the activities of complex I and its NADH dehydro-
genase (p  0.05 vs. control; n  5 per group) (Fig. 5B).
Nitrate supplementation protected both complex I and its
NADH dehydrogenase against DOX-induced damage.
Nitrate supplementation reduces lipid peroxidation.
Lipid peroxidation in the DOX group was increased by 38%
compared with the control group (n 6, p 0.05) (Fig. 6A),
which was completely suppressed by nitrate supplementa-
Figure 4 Effect of Nitrate Supplementation on DOX-Induced
Cell Death in Isolated Adult Mouse Cardiomyocytes
Both necrosis (A) and apoptosis (B) were significantly increased after 18 h of
in vitro exposure to 1 mol/l doxorubicin (DOX). The cardiomyocytes isolated
from the mice receiving long-term nitrate supplementation were more resistant
to DOX-induced necrotic (A) and apoptotic (B) cell death. Data are expressed
as mean  SEM (n  4 per group). *p  0.01 versus DOX; †p  0.05 versus
nitrate  DOX; #p  0.05 versus DOX. TUNEL  terminal deoxynucleotidyl
transferase deoxyuridine triphosphate nick end labeling.
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Nitrate Intake Reduces Doxorubicin Cardiotoxicity May 24, 2011:2181–9tion (p  0.05, nitrate  DOX group vs. control group)
Fig. 6A). Nitrate supplementation alone had no effect on
he oxidative markers.
itrate supplementation limits DOX-induced H2O2
generation. H2O2 was increased in mitochondria isolated
rom DOX-treated mice compared with the control group
hen glutamate and malate were used as a complex I
ubstrate (p  0.05) (Fig. 6B). Nitrate significantly de-
reased H2O2 generation when combined with DOX.
itrate alone had no effect on mitochondrial H2O2 gener-
tion. Similarly, nitrate supplementation attenuated DOX-
nduced H2O2 generation when succinate and rotenone
were used as a complex II substrate (Fig. 6B).
Subcutaneous infusion of nitrate fails to prevent DOX-
induced LV contractile dysfunction. To determine if a
nonoral route of nitrate supplementation could protect
against DOX cardiotoxicity, we implanted micro-osmotic
pumps subcutaneously in 2 groups of DOX-treated mice
(n  7 in each group) receiving continuous infusion of
either nitrate (NaNO3, 1 g/l concentration) or saline for
the same 13-day duration of oral nitrate supplementa-
tion. LV systolic (Online Figs. 2A and 2C) and diastolic
(Online Figs. 2B and 2D) functional parameters were not
improved by subcutaneous infusion of nitrate (p  0.05,
DOX vs. nitrate  DOX). The subcutaneous infusion
Figure 5 Effect of Nitrate Supplementation on DOX-Induced Inh
(A) Doxorubicin (DOX) treatment decreased the rate of glutamate and malate oxid
(complex II substrate) oxidation was not altered in the isolated mouse cardiac mit
dependent oxidative rate. (B) DOX treatment decreased the activity of complex I a
homogenate (*p  0.05 vs. control; n  5 per group). Nitrate treatment complete
nase activity (†p  0.05 vs. DOX). Data are expressed as mean  SEM.route increased plasma levels of nitrate (p  0.05, DOX avs. nitrate  DOX) (Online Fig. 2E), while nitrite levels
remained unchanged (Online Fig. 2F).
Discussion
DOX-induced cardiomyopathy remains a clinical dilemma
in oncology and cardiology practice (3) and has severely
limited the therapeutic potential of this potent anticancer
drug (2). We examined the effects of long-term oral sup-
plementation of nitrate against DOX-induced cardiomyop-
athy using a comprehensive approach to demonstrate pro-
tection at the level of intact organ, isolated cells, and
mitochondria. Nitrate supplementation caused significant
preservation of LV contractile function and decreased car-
diomyocyte death through mechanisms involving inhibition
of lipid peroxidation, reduction of mitochondrial complex I
damage, and attenuation of H2O2 generation in mice
reated with DOX. These results suggest that nitrate sup-
lementation could be a potentially novel treatment modal-
ty in alleviating DOX-induced cardiotoxicity in patients
ith cancer.
ardioprotective effects of nitrate supplementation:
ole of NO and NOS. Nitrite and nitrate have tradition-
lly been considered the inert end products of NO metab-
lism, with limited intrinsic biological activity (29). Nitrate
n of Mitochondrial Complex I
complex I substrate; *p  0.05 vs. control; n  6 per group), but succinate
ria. Nitrate supplementation completely prevented the impaired complex I–
otinamide adenine dinucleotide (NADH) dehydrogenase in the heart tissue
ntained complex I activity, whereas it only partially preserved NADH dehydroge-ibitio
ation (
ochond
nd nic
ly maind nitrite have recently emerged at the forefront of NO
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May 24, 2011:2181–9 Nitrate Intake Reduces Doxorubicin Cardiotoxicitybiology because they represent a major storage form of
NO in blood and tissues (30). It has been increasingly
appreciated that nitrate and nitrite can be reduced to NO
under tissue ischemia or hypoxia and acidosis (18,30 –32).
At extremely low tissue pH and partial pressure of oxygen
during myocardial ischemia, nitrite may be reduced to
NO by acidic disproportionation (15,33) or by the enzy-
matic reduction of xanthine oxidoreductase (34). The
NOS-independent pathway of NO production is an
important alternative system under pathological condi-
tions such as myocardial ischemia, because NO produc-
tion through this mechanism is critically influenced by
various cofactors and presence of oxygen. Therefore,
mobilization of the nitrate-nitrite-NO pathway is an
important alternative means to produce NO, which in
turn limits tissue injury under pathophysiological condi-
tions. Particularly, dietary nitrate or nitrite supplemen-
tation was recently found to be beneficial against myo-
cardial I/R injury (19,20), cardiac arrest–resuscitation,
and hypertension (21). The present study has extended
the potential use of nitrate supplementation in reducing
Figure 6 Effect of Nitrate Supplementation on DOX-Induced Tis
Lipid Peroxidation and H2O2 Generation From Isolated
(A) DOX-induced tissue lipid peroxidation and (B) H2O2 generation from isolated m
(succinate and rotenone) were used to identify the specific site(s) of hydrogen per
n  6 per group for A and n  5 to 8 per group for B. *p  0.05 versus all other
plus 4-hydroxyalkenals.myocardial damage caused by DOX. Our results provide aconclusive evidence that long-term nitrate supplementation
significantly reduced DOX-induced LV contractile dys-
function (Figs. 1 and 2), depressed central aortic pressure
Fig. 2F), and reduced cardiomyocyte necrotic and apoptotic
eath (Fig. 4). Most important, these cardioprotective effects
re associated with concomitant increases in plasma levels of
itrate and nitrite (i.e., NOx) (Fig. 3C), an indicator of
nhanced NO production.
The role of NOS-dependent versus NOS-independent
O generation in the nitrate-induced protection against
OX-induced cardiomyopathy remains largely elusive. Pre-
ious studies have suggested a detrimental role of iNOS-
erived NO in DOX-induced cardiomyopathy (35,36).
onversely, NO is a ubiquitous signaling molecule in
rotection against myocardial I/R injury by ischemic or
harmacological pre-conditioning (6). Additionally, anthra-
yclines produce distinct and largely irreversible changes in
evels of phosphate metabolites and substantial acidosis in
he heart (37), which could potentially trigger NOS-
ndependent protection induced by nitrite. Although the
ietary nitrite supplementation–induced cardioprotection
chondria
ndria. Complex I substrate (glutamate and malate) and complex II substrate
H2O2) generation in the mitochondria. Data are expressed as mean  SEM;
s; #p  0.05 versus doxorubicin (DOX) group. MDA4-HAE  malondialdehydesue
Mito
itocho
oxide (
groupgainst I/R injury has been reported to be eNOS indepen-
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Nitrate Intake Reduces Doxorubicin Cardiotoxicity May 24, 2011:2181–9dent (38), it is unclear whether this is the case with
DOX-induced myocardial dysfunction. Further studies are
necessary to delineate the potential role of NOS in nitrate-
mediated protection against DOX cardiomyopathy.
Another interesting observation was that DOX elevated
plasma nitrate levels without significant changes in nitrite
levels (with or without nitrate supplementation). The reason
is not clear, but it could presumably have resulted from the
enhanced NOS-dependent NO synthesis induced by DOX
treatment (Figs. 3A and 3B). This would suggest impeded
nitrate-to-nitrite conversion, possibly due to the antibiotic
property of DOX, which may have hindered bacterial
nitrate-to-nitrite conversion after DOX treatment. Never-
theless, overall NOx were significantly increased in the
nitrate DOX group compared with the DOX group (p 
.05) (Fig. 3C), suggesting an association between en-
anced NO production and nitrate-induced cardioprotec-
ion. It is noteworthy that although nitrate supplementation
esulted in a relatively small change in nitrite levels (Fig. 3B),
t caused large increases in NOx levels (Fig. 3C). The reason is
ot clear, although it is possible that a substantial amount of
O could be generated via the NOS-dependent pathway,
ecause both iNOS and eNOS were up-regulated in the heart
y nitrate supplementation (unpublished data). Future studies
re needed to examine the role of each of the NOS isoforms
i.e., iNOS, eNOS, and neuronal NOS) in nitrate-induced
ardioprotection against DOX cardiotoxicity.
ole of nitrate in protection of mitochondrial complex I.
OX-induced cardiomyopathy occurs primarily via the gen-
ration of ROS in mitochondria (24,25), a mechanism that is
eparate from its antineoplastic activity (39). Complex I and
omplex III of the mitochondria are the key sites for ROS
eneration (40), and DOX enhances ROS generation through
ts bioreductive activation, which converts DOX to a semiqui-
one radical via univalent reduction (24). Complex I, especially
ADH dehydrogenase (the initial segment of complex I), is
he key site for DOX bioreductive activation in cardiac cells
27,28). The increased generation of ROS from the ETC in
urn damages mitochondria and induces cell injury (40,41).
he cardiotoxicity of DOX is apparently dose dependent: A
ow concentration of DOX selectively damages NADH dehy-
rogenase by increasing oxidative stress, whereas a high con-
entration of DOX induces nonoxidative inactivation of the
omplexes at the ETC through the formation of a DOX-
ardiolipin complex (24,42). The present study showed that
OX impairs complex I by decreasing NADH dehydrogenase
ctivity (Fig. 5), which is protected by nitrate supplementation.
hese data suggest that the attenuated damage at the mito-
hondrial complex I level may at least partially explain the
itrate-induced protection against cardiotoxicity. Moreover,
hese results are conceptually consistent with the nitrosylation
f complex I through NO generation by nitrate or nitrite
26,43). Complex I nitrosylation results in the decrease of its
ctivity (44), thereby providing an acute, protective partial
lockade of electron transport (41,44). The transient blockade
f complex I during stress, including I/R, protects complex Ictivity and reduces cardiomyocyte injury (26). We propose
hat the analogous blockade of electron transport during DOX
xposure protects against mitochondrial and cardiac damage.
itrate supplementation suppresses DOX-induced oxidative
tress. DOX-enhanced tissue lipid peroxidation (Fig. 6A)
s well as mitochondrial H2O2 generation (Fig. 6B) were
ffectively diminished by long-term nitrate intake. These
ovel observations may represent a key mechanistic expla-
ation for the reduction of DOX-induced cardiotoxicity by
itrate supplementation.
ral administration of nitrate is critical for cardioprotection.
n interesting observation in the present study is the
ecessity of the oral route for nitrate-induced protection
gainst DOX cardiotoxicity. The long-term subcutaneous
nfusion of nitrate failed to significantly improve DOX-
nduced LV dysfunction (Online Figs. 2A to 2D), despite the
omparable plasma nitrate levels between the oral and subcu-
aneous routes of administration (Fig. 3A, Online Fig. 2E).
hese results suggest that the bacterial bioconversion and
eduction of nitrate in the mouth and lower gastrointestinal
ract are critical for initiation and/or maintenance of the
ardioprotective signals induced by nitrate supplementation.
herefore, an oral route of inorganic nitrate administration
s more effective in protection against DOX-induced
ardiomyopathy.
onclusions
e have provided the first evidence for the efficacy of
ong-term dietary nitrate supplementation to attenuate
OX-induced ventricular dysfunction, cell death, oxidative
tress, and mitochondrial respiratory chain damage. These
esults are potentially important in designing clinical trials
n nitrate supplementation as a prophylactic pharmacolog-
cal intervention to attenuate DOX-induced cardiomyopa-
hy in patients with cancer.
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APPENDIX
For a detailed Methods section and Online Figures 1 and 2,
please see the online version of this article.
